Company Presentation . Bigger Capital Blog Posts: Our Second Alzheimer's Investment: Neurotrope . Neurotrope Announces Positive Top-Line Results From Its Phase 2a Study of Bryostatin-1 in Alzheimer's Disease including an important comment about safety . Neurotrope Announces Positive Final Resu ...

On Friday, Neurotrope, Inc. ( NTRP ), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer's disease, announced that it entered into a definitive securities purchase agreement with accredited investors to raise approximately $20.2 million in a private placeme ...

Neurotrope (NTRP) will release its Bryostatin Phase 2b top line data this week (company’s guidance). The primary efficacy endpoint is based on Severe Impairment Battery Scale (SIB). Entry criteria was based on the MMSE score. Secondary efficacy endpoints were based on – Activities of Dai ...